Successful in vitro immortalization of human intestinal mucosal lymphocytes with Herpesvirus saimiri. 1998

J M Martin-Villa, and S Ferre-Lopez, and J C Lopez-Suarez, and M Pérez-Blas, and G Castellano-Tortajada, and F Sánchez-Gomez, and A Arnaiz-Villena
Departamento de Inmunología, Hospital Universitario 12 de Octubre, Universidad Complutense, Madrid, Spain. jmmvilla@eucmax.sim.ucm.es

Mucosal intestinal lymphocytes form the first immune-cell line of defense in the intestine. Several methodologies, most of them cumbersome and time consuming, have been used to obtain T-cell clones to unveil their physiological role. In the present work we take advantage of the recently described technique of transformation of T lymphocytes using Herpesvirus saimiri to show that it is possible to immortalize intestinal T-cell lines derived from healthy and diseased colonic samples and thence easily obtain in vitro intestinal T-cell lines as a model for physiopathological studies. Intestinal samples were obtained by colonoscopy and digested with dispase and collagenase. Mucosal lymphocytes (assessed by the expression of the CD3 and CD103 markers) were isolated using a Percoll gradient centrifugation and transformed with Herpesvirus saimiri. Sustained growth was observed 3 months later, showing that the cells were successfully transformed, a finding further confirmed by PCR. All cell lines were CD8+TcRalphabeta+ and HLA-DR+. CD25 was expressed on 1% of Crohn's disease-derived cells and on 25% of cells derived from patients with ulcerative colitis. CD80 expression was found on 80-90% of the cells. These immortal cell lines of intestinal origin may be useful in future experiments aimed at elucidating the role of mucosal lymphocytes in health and disease.

UI MeSH Term Description Entries
D007413 Intestinal Mucosa Lining of the INTESTINES, consisting of an inner EPITHELIUM, a middle LAMINA PROPRIA, and an outer MUSCULARIS MUCOSAE. In the SMALL INTESTINE, the mucosa is characterized by a series of folds and abundance of absorptive cells (ENTEROCYTES) with MICROVILLI. Intestinal Epithelium,Intestinal Glands,Epithelium, Intestinal,Gland, Intestinal,Glands, Intestinal,Intestinal Gland,Mucosa, Intestinal
D008562 Membrane Glycoproteins Glycoproteins found on the membrane or surface of cells. Cell Surface Glycoproteins,Surface Glycoproteins,Cell Surface Glycoprotein,Membrane Glycoprotein,Surface Glycoprotein,Glycoprotein, Cell Surface,Glycoprotein, Membrane,Glycoprotein, Surface,Glycoproteins, Cell Surface,Glycoproteins, Membrane,Glycoproteins, Surface,Surface Glycoprotein, Cell,Surface Glycoproteins, Cell
D006567 Herpesvirus 2, Saimiriine The type species of RHADINOVIRUS, in the subfamily GAMMAHERPESVIRINAE, isolated from squirrel monkeys. It produces malignant lymphomas (LYMPHOMA, MALIGNANT) in inoculated marmosets or owl monkeys. Herpesvirus 2, Saimirine,Herpesvirus 2 (gamma), Saimirine,Herpesvirus Saimiri,Saimiriine Herpesvirus 2,Saimirine Herpesvirus 2,Herpesvirus Saimirus,Saimiri, Herpesvirus,Saimirus, Herpesvirus
D006684 HLA-DR Antigens A subclass of HLA-D antigens that consist of alpha and beta chains. The inheritance of HLA-DR antigens differs from that of the HLA-DQ ANTIGENS and HLA-DP ANTIGENS. HLA-DR,Antigens, HLA-DR,HLA DR Antigens
D013601 T-Lymphocytes Lymphocytes responsible for cell-mediated immunity. Two types have been identified - cytotoxic (T-LYMPHOCYTES, CYTOTOXIC) and helper T-lymphocytes (T-LYMPHOCYTES, HELPER-INDUCER). They are formed when lymphocytes circulate through the THYMUS GLAND and differentiate to thymocytes. When exposed to an antigen, they divide rapidly and produce large numbers of new T cells sensitized to that antigen. T Cell,T Lymphocyte,T-Cells,Thymus-Dependent Lymphocytes,Cell, T,Cells, T,Lymphocyte, T,Lymphocyte, Thymus-Dependent,Lymphocytes, T,Lymphocytes, Thymus-Dependent,T Cells,T Lymphocytes,T-Cell,T-Lymphocyte,Thymus Dependent Lymphocytes,Thymus-Dependent Lymphocyte
D015212 Inflammatory Bowel Diseases Chronic, non-specific inflammation of the GASTROINTESTINAL TRACT. Etiology may be genetic or environmental. This term includes CROHN DISEASE and ULCERATIVE COLITIS. Bowel Diseases, Inflammatory,Inflammatory Bowel Disease
D015375 Receptors, Interleukin-2 Receptors present on activated T-LYMPHOCYTES and B-LYMPHOCYTES that are specific for INTERLEUKIN-2 and play an important role in LYMPHOCYTE ACTIVATION. They are heterotrimeric proteins consisting of the INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT, the INTERLEUKIN-2 RECEPTOR BETA SUBUNIT, and the INTERLEUKIN RECEPTOR COMMON GAMMA-CHAIN. IL-2 Receptors,Interleukin-2 Receptor,Interleukin-2 Receptors,Receptors, IL-2,Receptors, T-Cell Growth Factor,T-Cell Growth Factor Receptors,IL-2 Receptor,IL2 Receptor,IL2 Receptors,Interleukin 2 Receptor,Receptor, TCGF,T-Cell Growth Factor Receptor,TCGF Receptor,TCGF Receptors,IL 2 Receptor,IL 2 Receptors,Interleukin 2 Receptors,Receptor, IL-2,Receptor, IL2,Receptor, Interleukin 2,Receptor, Interleukin-2,Receptors, IL 2,Receptors, IL2,Receptors, Interleukin 2,Receptors, T Cell Growth Factor,Receptors, TCGF,T Cell Growth Factor Receptor,T Cell Growth Factor Receptors
D015415 Biomarkers Measurable and quantifiable biological parameters (e.g., specific enzyme concentration, specific hormone concentration, specific gene phenotype distribution in a population, presence of biological substances) which serve as indices for health- and physiology-related assessments, such as disease risk, psychiatric disorders, ENVIRONMENTAL EXPOSURE and its effects, disease diagnosis; METABOLIC PROCESSES; SUBSTANCE ABUSE; PREGNANCY; cell line development; EPIDEMIOLOGIC STUDIES; etc. Biochemical Markers,Biological Markers,Biomarker,Clinical Markers,Immunologic Markers,Laboratory Markers,Markers, Biochemical,Markers, Biological,Markers, Clinical,Markers, Immunologic,Markers, Laboratory,Markers, Serum,Markers, Surrogate,Markers, Viral,Serum Markers,Surrogate Markers,Viral Markers,Biochemical Marker,Biologic Marker,Biologic Markers,Clinical Marker,Immune Marker,Immune Markers,Immunologic Marker,Laboratory Marker,Marker, Biochemical,Marker, Biological,Marker, Clinical,Marker, Immunologic,Marker, Laboratory,Marker, Serum,Marker, Surrogate,Serum Marker,Surrogate End Point,Surrogate End Points,Surrogate Endpoint,Surrogate Endpoints,Surrogate Marker,Viral Marker,Biological Marker,End Point, Surrogate,End Points, Surrogate,Endpoint, Surrogate,Endpoints, Surrogate,Marker, Biologic,Marker, Immune,Marker, Viral,Markers, Biologic,Markers, Immune
D015703 Antigens, CD Differentiation antigens residing on mammalian leukocytes. CD stands for cluster of differentiation, which refers to groups of monoclonal antibodies that show similar reactivity with certain subpopulations of antigens of a particular lineage or differentiation stage. The subpopulations of antigens are also known by the same CD designation. CD Antigen,Cluster of Differentiation Antigen,Cluster of Differentiation Marker,Differentiation Antigens, Leukocyte, Human,Leukocyte Differentiation Antigens, Human,Cluster of Differentiation Antigens,Cluster of Differentiation Markers,Antigen Cluster, Differentiation,Antigen, CD,CD Antigens,Differentiation Antigen Cluster,Differentiation Marker Cluster,Marker Cluster, Differentiation
D051940 B7-2 Antigen A costimulatory ligand glycoprotein that contains a C2 and V-type IMMUNOGLOBULIN DOMAIN. It is expressed by ANTIGEN-PRESENTING CELLS and binds to CD28 ANTIGEN with high specificity and to CTLA-4 ANTIGEN with low specificity. The interaction of CD86 with CD28 ANTIGEN provides a stimulatory signal to T-LYMPHOCYTES, while its interaction with CTLA-4 ANTIGEN may play a role in inducing PERIPHERAL TOLERANCE. Antigens, CD86,B7-2 Costimulatory Molecule,CD86 Antigens,Antigen, B7-2,B70 Costimulatory Molecule,CD86 Antigen,Early T Cell Costimulatory Molecule 1,Antigen, B7 2,Antigen, CD86,B7 2 Antigen,Costimulatory Molecule, B7-2,Costimulatory Molecule, B70

Related Publications

J M Martin-Villa, and S Ferre-Lopez, and J C Lopez-Suarez, and M Pérez-Blas, and G Castellano-Tortajada, and F Sánchez-Gomez, and A Arnaiz-Villena
February 1995, Immunology today,
J M Martin-Villa, and S Ferre-Lopez, and J C Lopez-Suarez, and M Pérez-Blas, and G Castellano-Tortajada, and F Sánchez-Gomez, and A Arnaiz-Villena
November 1987, Journal of virology,
J M Martin-Villa, and S Ferre-Lopez, and J C Lopez-Suarez, and M Pérez-Blas, and G Castellano-Tortajada, and F Sánchez-Gomez, and A Arnaiz-Villena
April 1996, Virology,
J M Martin-Villa, and S Ferre-Lopez, and J C Lopez-Suarez, and M Pérez-Blas, and G Castellano-Tortajada, and F Sánchez-Gomez, and A Arnaiz-Villena
February 1986, Journal of virology,
J M Martin-Villa, and S Ferre-Lopez, and J C Lopez-Suarez, and M Pérez-Blas, and G Castellano-Tortajada, and F Sánchez-Gomez, and A Arnaiz-Villena
November 2004, Current protocols in immunology,
J M Martin-Villa, and S Ferre-Lopez, and J C Lopez-Suarez, and M Pérez-Blas, and G Castellano-Tortajada, and F Sánchez-Gomez, and A Arnaiz-Villena
December 1995, Journal of virology,
J M Martin-Villa, and S Ferre-Lopez, and J C Lopez-Suarez, and M Pérez-Blas, and G Castellano-Tortajada, and F Sánchez-Gomez, and A Arnaiz-Villena
April 1992, Proceedings of the National Academy of Sciences of the United States of America,
J M Martin-Villa, and S Ferre-Lopez, and J C Lopez-Suarez, and M Pérez-Blas, and G Castellano-Tortajada, and F Sánchez-Gomez, and A Arnaiz-Villena
September 2002, AIDS research and human retroviruses,
J M Martin-Villa, and S Ferre-Lopez, and J C Lopez-Suarez, and M Pérez-Blas, and G Castellano-Tortajada, and F Sánchez-Gomez, and A Arnaiz-Villena
June 1995, Proceedings of the National Academy of Sciences of the United States of America,
J M Martin-Villa, and S Ferre-Lopez, and J C Lopez-Suarez, and M Pérez-Blas, and G Castellano-Tortajada, and F Sánchez-Gomez, and A Arnaiz-Villena
November 1996, International immunology,
Copied contents to your clipboard!